Defence Therapeutics Inc. (OTCMKTS:DTCFF) Sees Significant Decline in Short Interest

Defence Therapeutics Inc. (OTCMKTS:DTCFF) saw a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 2,900 shares, a drop of 29.3% from the January 31st total of 4,100 shares. Based on an average daily volume of 4,300 shares, the days-to-cover ratio is presently 0.7 days.

Defence Therapeutics Price Performance

Shares of OTCMKTS DTCFF remained flat at $0.79 during trading hours on Wednesday. The business has a 50 day simple moving average of $0.64 and a 200-day simple moving average of $0.50. Defence Therapeutics has a 52-week low of $0.27 and a 52-week high of $1.32.

About Defence Therapeutics

Defence Therapeutics Inc engages in development of a biological drug enhancer platform that improves the efficacy and safety of a multitude of biological/biosimilar based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on development of vaccine for infectious disease and virus utilizing the ACCUMTM platform for drug delivery and effective treatments.